Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Neoplasm Recurrence, Local 1Lung Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 3Cisplatin 3Fluorouracil 2tislelizumab 1pembrolizumab 1motexafin gadolinium 1Tamoxifen 1Talaporfin 1TP protocol 1Spinal Puncture 1Rhenium 1Radiosurgery 1Poly I-C 1Paclitaxel 1Oxaliplatin 1Mitomycin 1Lomustine 1Irinotecan 1Gemcitabine 1Gadolinium 1Folfox protocol 1Ethiodized Oil 1Erlotinib Hydrochloride 1Docetaxel 1Cetuximab 1Carboplatin 1Blood Specimen Collection 1Bevacizumab 1Anesthesia, General 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Recurrence, Local × Rhenium × Clear all
NCT00100256 2022-11-07

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

Andarix Pharmaceuticals

Phase 1/2 Unknown
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Recurrence, Local, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡